Human Microbiome companies

Key Human Microbiome Market Players:

Here is a list of key players operating in the global market:

• Vedanta Biosciences (U.S)
• Seres Therapeutics (U.S.)
• Second Genome (U.S.)
• Rebiotix (Ferring Company) (U.S.)
• ActoGeniX (U.S)
• Enterome Bioscience (France)
• 4D Pharma Research Ltd. (Japan)
• Yakult Honsha (Japan)
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis

The competitors of the market are competing in terms of pricing and quality, which is leading to the development of cost-effective and high-quality probiotics. The market also experiences significant threats from well-established players because of advanced research and production equipment, which supports the growth of established businesses. Existing players keep developing their portfolios. The growing adoption of modern technologies among the key players is significantly supporting the growth of the human microbiome market.

Corporate Landscape of Human Microbiome Market

• Seres Therapeutic is a biotechnology business that develops products to restore the functioning of the microbiome in the human body. The business focuses on the production of live drugs and targets serious diseases, restoring healthy bacteria. The business is also behind the production of the first oral microbial solution. With a global presence, the organization is delivering high-quality drugs that support immune systems and allow patients to recover faster.
• Second Genome is a U.S. based lifescience research organization that studies the human microbiome and its various therapies. The platforms enable the assessment of human physiology and microbiota types, which can help tailor medicines and therapies for the patients. The company has also combined machine learning and analytics for protein engineering and phage display that uncovers the biomarkers associated with human body.
• Rebiotix is a biotechnology company that focuses on microbiota-based therapies and was acquired by Ferring Pharmaceuticals. The business is also known for its own Microbiota Restoration that can seamlessly manage the healthy gut and enhance wellbeing. The business has a global footprint because of high-end therapies at affordable costs. It has specifically broadened deliver of the drugs by developing oral medicines.
• Enterome Bioscience is a leading clinical-stage, biopharmaceutical company that has strong research and innovation skills. The medicines and therapies innovated by the business are highly effective, enhancing their adoption in the global market. With a large global footprint, it is leading the oncology and immune-generated diseases. It has collaborated with large number of research institutes for biomarker discovery.